Disease-Modifying Approaches Targeting Type 1 Diabetes: A Systematic Review and Meta-Analysis

Abstract

Background: Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, leading to insulin deficiency. While exogenous insulin therapy manages hyperglycemia, it does not address the underlying autoimmune pathology or halt disease progression.

Objective: To evaluate the efficacy and safety of immunotherapeutic agents in modifying disease progression in T1DM, focusing on glycemic control, β-cell preservation, and adverse events.

Methods: A systematic review and meta-analysis were conducted by the PRISMA guidelines. Randomized Controlled Trials (RCTs) involving immunotherapies such as anti-CD3 monoclonal antibodies (e.g., teplizumab), interleukin-2 modulators, antigen-specific vaccines, and mesenchymal stromal cell therapies were included. Primary outcomes assessed were changes in glycated hemoglobin (HbA1c) and C-peptide levels. Secondary outcomes included insulin dosage requirements and incidence of hypoglycemic episodes. Data were synthesized using a random-effects model, and heterogeneity was evaluated using the I²statistic.

Results: Twenty-eight Randomized Controlled Trials (RCTs) encompassing diverse immunotherapeutic interventions were analyzed. Immunotherapies demonstrated a modest but statistically significant reduction in HbA1c levels (mean difference: –0.48%; 95% CI: –0.61 to –0.35; p<0.001; I² = 72%). Additionally, there was a significant preservation of C-peptide levels (mean difference: +0.18 ng/mL; 95% CI: +0.05 to +0.31; p = 0.007; I² = 58%), indicating maintained β-cell function. Subgroup analyses revealed greater efficacy in pediatric populations and studies utilizing continuous glucose monitoring. Sensitivity analyses confirmed the robustness of these findings. Adverse events were generally mild to moderate, with no significant increase in hypoglycemic episodes reported.

Conclusion: Immunotherapeutic interventions in T1DM are associated with improved glycemic control and preservation of endogenous insulin secretion, particularly in younger patients and when combined with advanced glucose monitoring technologies. Future large-scale, long-term RCTs are warranted to confirm these findings and to facilitate the integration of immunotherapies into standard clinical practice for T1DM management.